Michael Rettig, PhD

Medical School Department Internal Medicine
Research Program Hematopoietic Development & Malignancy
Michael Rettig

Researcher Background

Primary Academic Title

Professor of Medicine, Division of Oncology, Section of Stem Cell Biology, WashU Medicine

Training

  • 2000 - 2003: Postdoctoral Fellow, Oncology, WashU Medicine, St. Louis, MO

Education

  • 2000: PhD, Chemistry, Purdue University, West Lafayette, IN

Research & Selected Publications

Research Interest

Developing strategies that will maximize the graft-versus-leukemia (GVL) effect while minimizing graft- versus-host disease (GVHD) after allogeneic hematopoietic stem-cell transplantation.

Research Publications

A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma.
Authors:

Pilcher WC, Yao L, Gonzalez-Kozlova E, one or more additional authors omitted Rettig MP, one or more additional authors omitted Bhasin M

Journal & Year:

Nat Cancer • 2026

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies.
Authors:

Ghobadi A, Aldoss I, Maude SL, one or more additional authors omitted Rettig MP, one or more additional authors omitted DiPersio JF

Journal & Year:

Blood • 2025

Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation.
Authors:

Abboud R, Schroeder MA, Rettig MP, one or more additional authors omitted DiPersio JF

Journal & Year:

Blood • 2025

An "off-the-shelf" CD2 universal CAR-T therapy for T-cell malignancies.
Authors:

Xiang J, Devenport JM, Carter AJ, one or more additional authors omitted Rettig MP, one or more additional authors omitted DiPersio JF

Journal & Year:

Leukemia • 2023